Open Access

Sodium lactate for fluid resuscitation: the preferred solution for the coming decades?

Critical Care201418:163

https://doi.org/10.1186/cc13973

Published: 7 July 2014

Abstract

In a recent issue of Critical Care, 0.5 M sodium lactate infusion for 24 hours was reported to increase cardiac output in patients with acute heart failure. This effect was associated with a concomitant metabolic alkalosis and a negative water balance. Growing data strongly support the role of lactate as a preferential oxidizable substrate to supply energy metabolism leading to improved organ function (heart and brain especially) in ischemic conditions. Due to its sodium/chloride imbalance, this solution prevents hyperchloremic acidosis and limits fluid overload despite the obligatory high sodium load. Sodium lactate solution therefore shows many advantages and appears a very promising means for resuscitation of critically ill patients. Further studies are needed to establish the most appropriate dose and indications for sodium lactate infusion in order to prevent the occurrence of severe hypernatremia and metabolic alkalosis.

In a recent issue of Critical Care, Nalos and colleagues evaluated the effect of 0.5 M sodium lactate (SL) solution on cardiac function in patients presenting acute heart failure [1]. The key result was that 24-hour infusion of SL resulted in increased cardiac output, whereas it did not change in the control group receiving Ringer lactate. This difference could be accounted for, in large part, by an augmentation in stroke volume. Further, patients receiving SL developed metabolic alkalosis, hypokalemia and hypernatremia, while their water balance was strongly negative. These findings highlight the complexity of the beneficial effects induced by SL infusion.

First, hyperlactatemia is a good marker of poor outcome in critically ill patients. Tissue hypoxia is responsible for an increased lactate production resulting from glycolysis [2, 3]. Proponents of intensive intervention therefore strongly believed that lactate was, to say the least, a useless waste end product, if not a toxic one. However, the cause–effect relationship is not clearly demonstrated. Indeed, growing data support the notion that lactate production is not deleterious, but rather is an adaptative response allowing one to maintain an appropriate energetic metabolism in the case of shock or organ failure [24]. Nevertheless, the effect of solutions containing high lactate concentration in these situations is still a matter of debate.

Evidence is now accumulating that lactate is a preferred substrate readily oxidizable in energy crisis conditions [46]. In physiological basal situations, the myocardium functions using energy from beta-oxidation of fatty acids. When oxygen availability is limited, myocardial energy metabolism switches from lipid oxidation to carbohydrate oxidation [7]. Previous studies have already shown that lactate infusion was responsible for an improved myocardial function in patients with septic shock or after cardiac surgery [4, 8, 9]. The current study reproduces these results in patients with acute heart failure [1]. Levy and colleagues demonstrated that lactate deprivation worsened myocardial metabolism and performance in rats with septic shock [4]. This effect is believed to be due to, for the greater part, the preferential lactate metabolism supplying sufficient energy to the myocardium. However, this hypothesis should be confirmed using direct measurements of lactate oxidation in the heart. Similar results have been reported in normal and injured brain, and confirmed the role of lactate as an important source of energy [6, 10, 11]. Allaman and colleagues described the essential impact of lactate metabolism in the astrocyte–neuron coupling function [12]. In traumatic brain injury, SL infusion was more efficient than mannitol to decrease raised intracranial pressure [11]. In a later study, a systematic SL infusion over 48 hours decreased by 50% the incidence of elevated intracranial pressure episodes [13].

The second point raised by Nalos and colleagues is the induction of metabolic alkalosis by SL infusion [1], which reflects the probable lactate oxidation. According to the Stewart concept, the exogenous lactate enters into the cells (metabolized anion) while exogenous sodium remains in the plasma (nonmetabolized cation). These modifications in turn induce an increase in the strong ion difference and in the plasma bicarbonate concentration [14]. In agreement with other studies, SL infusion induced metabolic alkalosis and hypokalemia and prevented hyperchloremic acidosis. The authors emphasized that metabolic alkalosis could improve cardiac function [1]. However, it is known that metabolic alkalosis decreases coronary artery blood flow and worsens cardiac arrhythmias, hypokalemia and cardiac contractility. On the other hand, prevention of hyperchloremic acidosis by the balanced SL solution could lead to an improvement in organ function [15, 16]. The global consequences of such multiple and intricate metabolic modifications on cardiac function remain questioned.

Third, the infusion of a large amount of sodium in patients with acute heart failure represents a clear danger as sodium restriction is the classic treatment for this condition. Surprisingly, the authors showed that the 24-hour and 48-hour water balances were strongly negative in patients receiving SL compared with the control group. This finding is in agreement with previous studies performed in cardiac surgery and traumatic brain-injured patients [9, 11]. The mechanism by which SL influences water balance is not clear. A lower required volume of infusion and/or a higher urine output have been previously reported as a consequence of the sodium/chloride imbalance of this solution [9, 11]. Unfortunately, these data are lacking in the study by Nalos and colleagues. Independently of the underlying mechanism, the resulting effect provides a substantial advantage in favor of SL infusion because fluid overload is associated with an increased morbi-mortality in various critical conditions, especially cardiac failure [17].

In conclusion, the study by Nalos and colleagues provides additional arguments to strongly consider SL as a valuable means for resuscitation. Thanks to its high lactate and low chloride concentrations, SL offers substantial clinical improvement in organ functions, especially for the heart and brain.

Abbreviations

SL: 

sodium lactate.

Declarations

Authors’ Affiliations

(1)
Medicosurgical Intensive Care Unit, Saint Roch University Hospital
(2)
INSERM, U1081, Institute for Research on Cancer and Aging of Nice (IRCAN), ‘Aging and Diabetes’ Team
(3)
CNRS, UMR7284, IRCAN
(4)
University of Nice – Sophia Antipolis
(5)
LBFA – INSERM 1055, University Joseph Fourier

References

  1. Nalos M, Leverve XM, Huang SJ, Weisbrodt L, Parkin R, Seppelt IM, Ting I, Mclean AS: Half-molar sodium lactate infusion improves cardiac performance in acute heart failure: a pilot randomized controlled clinical trial. Crit Care. 2014, 18: R48-10.1186/cc13793.PubMed CentralView ArticlePubMedGoogle Scholar
  2. Bakker J, Nijsten MWN, Jansen TC: Clinical use of lactate monitoring in critically ill patients. Ann Intensive Care. 2013, 3: 12-10.1186/2110-5820-3-12.PubMed CentralView ArticlePubMedGoogle Scholar
  3. Garcia-Alvarez M, Marik P, Bellomo R: Stress hyperlactataemia: present understanding and controversy. Lancet Diabetes Endocrinol. 2014, 2: 339-347. 10.1016/S2213-8587(13)70154-2.View ArticlePubMedGoogle Scholar
  4. Levy B, Mansart A, Montenmont C, Gibot S, Mallie JP, Lacolley P: Myocardial lactate deprivation is associated with decreased cardiovascular performance, decreased myocardial energetics and early death in endotoxic shock. Intensive Care Med. 2007, 33: 495-505. 10.1007/s00134-006-0523-9.View ArticlePubMedGoogle Scholar
  5. Van Hall G: Lactate kinetics in human tissues at rest and during exercise. Acta Physiol. 2010, 199: 499-508. 10.1111/j.1748-1716.2010.02122.x.View ArticleGoogle Scholar
  6. Wyss MT, Jolivet R, Buck A, Magistratti PJ, Weber B: In vivo evidence for lactate as a neuronal energy source. J Neurosci. 2011, 31: 7477-7485. 10.1523/JNEUROSCI.0415-11.2011.View ArticlePubMedGoogle Scholar
  7. Stanley WC, Recchia FA, Lopaschuk GD: Myocardial substrate metabolism in the normal and failing heart. Physiol Rev. 2005, 85: 1093-1129. 10.1152/physrev.00006.2004.View ArticlePubMedGoogle Scholar
  8. Mustafa I, Leverve XM: Metabolic and hemodynamic effects of hypertonic solutions: sodium-lactate versus sodium chloride infusion in postoperative patients. Shock. 2002, 18: 306-310. 10.1097/00024382-200210000-00003.View ArticlePubMedGoogle Scholar
  9. Leverve XC, Boon C, Hakim T, Anwar M, Siregar E, Mustafa I: Half-molar sodium-lactate solution has beneficial effect in patients after coronary artery bypass grafting. Intensive Care Med. 2008, 34: 1796-1803. 10.1007/s00134-008-1165-x.View ArticlePubMedGoogle Scholar
  10. Bouzat P, Sala N, Suys T, Zerlauth JB, Marques-Vidal P, Feihl F, Bloch J, Messerer M, Levivier M, Meuli R, Magistretti PJ, Oddo M: Cerebral metabolic effects of exogenous lactate supplementation on the injured human brain. Intensive Care Med. 2014, 40: 412-421. 10.1007/s00134-013-3203-6.View ArticlePubMedGoogle Scholar
  11. Ichai C, Armando G, Orban JC, Berthier F, Rami L, Samat-Long C, Grimaud D, Leverve X: Sodium-lactate vs mannitol in the treatment of intracranial hypertensive episodes in severe traumatic brain-injured patients. Intensive Care Med. 2009, 35: 471-479. 10.1007/s00134-008-1283-5.View ArticlePubMedGoogle Scholar
  12. Allaman I, Bélanger M, Magistretti PJ: Astrocyte–neuron metabolism relationships: for better and for worse. Trends Neurosci. 2011, 34: 76-87. 10.1016/j.tins.2010.12.001.View ArticlePubMedGoogle Scholar
  13. Ichai C, Payen JF, Orban JC, Quintard H, Roth H, Legrand R, Francony G, Leverve X: Half-molar sodium lactate to prevent intracranial hypertensive episodes in severe traumatic brain-injured patients: a randomized controlled trial. Intensive Care Med. 2013, 39: 1413-1422. 10.1007/s00134-013-2978-9.View ArticlePubMedGoogle Scholar
  14. Stewart PA: Independent and dependent variables of acid–base control. Resp Physiol. 1978, 33: 9-26. 10.1016/0034-5687(78)90079-8.View ArticleGoogle Scholar
  15. Yunos LM, Bellomo R, Hegarty C, Story D, Ho L, Bailey M: Association between a chloride-liberal vs chloride-restrictive intravenous fluid. JAMA. 2012, 308: 1566-1572. 10.1001/jama.2012.13356.View ArticlePubMedGoogle Scholar
  16. McCluskey SA, Karkouti K, Wijeysundera D, Minkovich L, Tait G, Beattie WS: Hyperchloremia after noncardiac surgery is independently associated with increased morbidity and mortality: a propensity-matched cohort study. Anesth Analg. 2013, 117: 412-421. 10.1213/ANE.0b013e318293d81e.View ArticlePubMedGoogle Scholar
  17. Vincent JL, Sakr Y, Sprung CL, Ranieri VM, Reinhart K, Gerlach H, Moreno R, Carlet J, Le Gall JR, Payen D, Sepsis Occurrence in Acute Ill Patients Investigators: Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006, 34: 344-353. 10.1097/01.CCM.0000194725.48928.3A.View ArticlePubMedGoogle Scholar

Copyright

© Ichai et al.; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement